Literature DB >> 33546432

Clinical Progress in Proton Radiotherapy: Biological Unknowns.

Laura Vanderwaeren1,2,3, Rüveyda Dok1, Kevin Verstrepen2,3, Sandra Nuyts1,4.   

Abstract

Clinical use of proton radiation has massively increased over the past years. The main reason for this is the beneficial depth-dose distribution of protons that allows to reduce toxicity to normal tissues surrounding the tumor. Despite the experience in the clinical use of protons, the radiobiology after proton irradiation compared to photon irradiation remains to be completely elucidated. Proton radiation may lead to differential damages and activation of biological processes. Here, we will review the current knowledge of proton radiobiology in terms of induction of reactive oxygen species, hypoxia, DNA damage response, as well as cell death after proton irradiation and radioresistance.

Entities:  

Keywords:  proton radiation; radiobiology; radiotherapy

Year:  2021        PMID: 33546432      PMCID: PMC7913745          DOI: 10.3390/cancers13040604

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  111 in total

1.  The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines.

Authors:  Geoff Delaney; Susannah Jacob; Carolyn Featherstone; Michael Barton
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

2.  Differential activation of mitogen-activated protein kinases following high and low LET radiation in murine macrophage cell line.

Authors:  Himanshi Narang; Nagesh Bhat; S K Gupta; S Santra; R K Choudhary; S Kailash; Malini Krishna
Journal:  Mol Cell Biochem       Date:  2008-12-27       Impact factor: 3.396

3.  Cycling hypoxia increases U87 glioma cell radioresistance via ROS induced higher and long-term HIF-1 signal transduction activity.

Authors:  Chia-Hung Hsieh; Cheng-Hung Lee; Ji-An Liang; Chun-Yen Yu; Woei-Cherng Shyu
Journal:  Oncol Rep       Date:  2010-12       Impact factor: 3.906

4.  Response of a human melanoma cell line to low and high ionizing radiation.

Authors:  Aleksandra M Ristic-Fira; Danijela V Todorovic; Lela B Koricanac; Ivan M Petrovic; Lucia M Valastro; Pablo G A Cirrone; Luigi Raffaele; Giacomo Cuttone
Journal:  Ann N Y Acad Sci       Date:  2007-01       Impact factor: 5.691

Review 5.  Radiation-induced cell death mechanisms.

Authors:  David Eriksson; Torgny Stigbrand
Journal:  Tumour Biol       Date:  2010-05-20

6.  Deficiency in homologous recombination renders Mammalian cells more sensitive to proton versus photon irradiation.

Authors:  Nicole Grosse; Andrea O Fontana; Eugen B Hug; Antony Lomax; Adolf Coray; Marc Augsburger; Harald Paganetti; Alessandro A Sartori; Martin Pruschy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-11-13       Impact factor: 7.038

7.  Low energy proton beam induces tumor cell apoptosis through reactive oxygen species and activation of caspases.

Authors:  Kheun Byeol Lee; Jong Soo Lee; Jeen Woo Park; Tae Lin Huh; You Mie Lee
Journal:  Exp Mol Med       Date:  2008-02-29       Impact factor: 8.718

Review 8.  Ionizing Radiation and Complex DNA Damage: From Prediction to Detection Challenges and Biological Significance.

Authors:  Ifigeneia V Mavragani; Zacharenia Nikitaki; Spyridon A Kalospyros; Alexandros G Georgakilas
Journal:  Cancers (Basel)       Date:  2019-11-14       Impact factor: 6.639

Review 9.  HIF-1α pathway: role, regulation and intervention for cancer therapy.

Authors:  Georgina N Masoud; Wei Li
Journal:  Acta Pharm Sin B       Date:  2015-06-06       Impact factor: 11.413

Review 10.  New insights in the relative radiobiological effectiveness of proton irradiation.

Authors:  K Ilicic; S E Combs; T E Schmid
Journal:  Radiat Oncol       Date:  2018-01-16       Impact factor: 3.481

View more
  1 in total

1.  miR-200a/b/-429 downregulation is a candidate biomarker of tumor radioresistance and independent of hypoxia in locally advanced cervical cancer.

Authors:  Anja Nilsen; Tiril Hillestad; Vilde E Skingen; Eva-Katrine Aarnes; Christina S Fjeldbo; Tord Hompland; Tina Sandø Evensen; Trond Stokke; Gunnar B Kristensen; Beata Grallert; Heidi Lyng
Journal:  Mol Oncol       Date:  2022-02-15       Impact factor: 6.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.